Abstract
Most clinicians prescribe an empiric PPI trial for patients presenting with typical GERD symptoms in the absence of alarm features, but there are limited data available from randomized trials to support this approach. In this Practice Point commentary I discuss the findings and limitations of a randomized study conducted by Giannini and colleagues that evaluated the use of empiric therapy with esomeprazole versus endoscopy-oriented therapy for the initial management of patients with typical symptoms of GERD without alarm features. The results suggest that an empiric PPI trial has similar efficacy to, and is more cost-effective than, endoscopy-oriented therapy. However, I caution that the application of these results might not extend to patients with atypical presentations of GERD, and highlight the possibility that other diagnostic tools such as reflux monitoring or new endoscopic modalities might yield superior results to both empiric and endoscopy-oriented therapies in this setting.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Giannini EG et al. (2008) Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment. Am J Gastroenterol 103: 267–275
DeVault KR and Castell DO (2005) Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100: 190–200
Fass R et al. (2005) Systematic Review: proton-pump inhibitor failure in gastro-oesophageal reflux disease—where next? Aliment Pharmacol Ther 22: 79–94
Dean BB et al. (2004) Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2: 656–664
Numans ME et al. (2004) Short-term treatment with proton-pump inhibitors as a test for gastroesopahgeal reflux disease. Ann Intern Med 140: 518–527
Author information
Authors and Affiliations
Ethics declarations
Competing interests
M Vela is on the Speaker's Bureau for AstraZeneca and is a Consultant for Medtronic.
Rights and permissions
About this article
Cite this article
Vela, M. Empiric PPI therapy or endoscopy for the initial management of patients with GERD in the absence of alarm features?. Nat Rev Gastroenterol Hepatol 5, 548–549 (2008). https://doi.org/10.1038/ncpgasthep1228
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep1228